<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310087</url>
  </required_header>
  <id_info>
    <org_study_id>UMCLjubljana-20140041</org_study_id>
    <nct_id>NCT02310087</nct_id>
  </id_info>
  <brief_title>Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures</brief_title>
  <acronym>Astax-ART</acronym>
  <official_title>Effect of Oral Administration of Astaxanthin on Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether administration of dietary supplement of
      astaxanthin with vitamin E improves the quality of sperm, fertilization and embryo
      development in Assisted Reproduction Techniques (ART) procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study male patients diagnosed with oligoasthenozoospermia - with an abnormal sperm
      concentration and motility, irrespective of the morphology of spermatozoa - treated with
      their female partner with assisted reproduction techniques (ISCI) will be included. In the
      double blind study male patients will be given astaxanthin with vitamin E (study group, 40
      patients) or placebo (control group, 40 patients) for three months prior to ART. In the study
      and the control group the quality of sperm (spermiogram), DNA fragmentation and mitochondrial
      membrane potential of semen before and after the dietary supplementation will be evaluated.
      In the ART procedure (ICSI) the fertilization rate, the quality of embryos, pregnancy rates
      and miscarriages rates in 1st trimester will be compared between the study and control group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>semen quality</measure>
    <time_frame>three months</time_frame>
    <description>In semen quality the spermiogram, DNA fragmentation and mitochondrial membrane potential before and after the intervention will be evaluated. The DNA fragmentation will be evaluated by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL) method, and mitochondrial membrane potential with carbocyanine fluorochrome DiOC6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>follicle stimulating hormone (FSH)</measure>
    <time_frame>three months</time_frame>
    <description>FSH levels in before and after the intervention will be evaluated in infertile men with oligoasthenozoospermia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization and embryo development in Assisted Reproduction Techniques (ART)</measure>
    <time_frame>six months</time_frame>
    <description>Fertilization rates and the quality of embryo development on day 3 in ICSI procedure in infertile couples will be determined after the three months of dietary supplementation of astaxanthin with vitamin E taken by infertile men with oligoasthenozoospermia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rates and miscarriage rates in 1st trimester after ART</measure>
    <time_frame>nine months</time_frame>
    <description>Pregnancy rates and miscarriage rates in 1st trimester after ART will be determined after the three months of dietary supplementation of astaxanthin with vitamin E taken by infertile men with oligoasthenozoospermia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>astaxanthin with vitamin E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>astaxanthin with vitamin E</intervention_name>
    <description>Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.</description>
    <arm_group_label>astaxanthin with vitamin E</arm_group_label>
    <other_name>Astasan, Sensilab, Slovenia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four tablets of placebo daily, taken at once. Continuously for three months.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  oligoasthenozoospermia with of without teratozoospermia by WHO criteria from the year
             2010

          -  fresh semen

          -  female partner younger than 38 years

          -  idiopathic or tubal infertility in female partners

          -  at least 4 oocytes retrieved in previous ovarian punction in ART cycle, if previously
             performed

          -  1st, 2nd or 3rd cycle of ART

        Exclusion Criteria:

          -  genetic indication for ART procedure

          -  donated semen

          -  polycystic ovary syndrome in female partner

          -  dietary supplementation intake of antioxidants (selenium, zink, vitamin E, vitamin C,
             vitamin A) in male participant in the last three months

          -  smoking in male participant &gt;20 cigarettes per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bojana Pinter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Ob/Gyn, University Medical Centre Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bojana Pinter, MD, PhD</last_name>
    <phone>+386-41-718-923</phone>
    <email>bojana.pinter@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senka Imamovic Kumalic, MD</last_name>
    <phone>+386-40-614-904</phone>
    <email>senka81@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Ob/Gyn, University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojana Pinter, MD, PhD</last_name>
      <phone>+386-41-718-923</phone>
      <email>bojana.pinter@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Senka Imamovic Kumalic, MD</last_name>
      <phone>+386-40-614-904</phone>
      <email>senka81@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Imamovic Kumalic S, Pinter B. Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia. Biomed Res Int. 2014;2014:426951. doi: 10.1155/2014/426951. Epub 2014 Mar 31. Review.</citation>
    <PMID>24800224</PMID>
  </reference>
  <reference>
    <citation>Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol Nutr Food Res. 2011 Jan;55(1):150-65. doi: 10.1002/mnfr.201000414. Epub 2010 Nov 18. Review.</citation>
    <PMID>21207519</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Nallella KP, Allamaneni SS, Said TM. Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online. 2004 Jun;8(6):616-27. Review.</citation>
    <PMID>15169573</PMID>
  </reference>
  <reference>
    <citation>Higuera-Ciapara I, Félix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185-96. Review.</citation>
    <PMID>16431409</PMID>
  </reference>
  <reference>
    <citation>Comhaire FH, El Garem Y, Mahmoud A, Eertmans F, Schoonjans F. Combined conventional/antioxidant &quot;Astaxanthin&quot; treatment for male infertility: a double blind, randomized trial. Asian J Androl. 2005 Sep;7(3):257-62.</citation>
    <PMID>16110353</PMID>
  </reference>
  <reference>
    <citation>Franco JG Jr, Baruffi RL, Mauri AL, Petersen CG, Oliveira JB, Vagnini L. Significance of large nuclear vacuoles in human spermatozoa: implications for ICSI. Reprod Biomed Online. 2008 Jul;17(1):42-5.</citation>
    <PMID>18616888</PMID>
  </reference>
  <reference>
    <citation>Chemes EH, Rawe YV. Sperm pathology: a step beyond descriptive morphology. Origin, characterization and fertility potential of abnormal sperm phenotypes in infertile men. Hum Reprod Update. 2003 Sep-Oct;9(5):405-28. Review.</citation>
    <PMID>14640375</PMID>
  </reference>
  <reference>
    <citation>Virro MR, Larson-Cook KL, Evenson DP. Sperm chromatin structure assay (SCSA) parameters are related to fertilization, blastocyst development, and ongoing pregnancy in in vitro fertilization and intracytoplasmic sperm injection cycles. Fertil Steril. 2004 May;81(5):1289-95.</citation>
    <PMID>15136092</PMID>
  </reference>
  <reference>
    <citation>Marchetti C, Obert G, Deffosez A, Formstecher P, Marchetti P. Study of mitochondrial membrane potential, reactive oxygen species, DNA fragmentation and cell viability by flow cytometry in human sperm. Hum Reprod. 2002 May;17(5):1257-65.</citation>
    <PMID>11980749</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Bojana Pinter</investigator_full_name>
    <investigator_title>Assoc. Prof., MD, PhD, Spec in Ob/Gyn, MS (Econ)</investigator_title>
  </responsible_party>
  <keyword>male infertility</keyword>
  <keyword>spermatogenesis</keyword>
  <keyword>antioxidants</keyword>
  <keyword>DNA damage</keyword>
  <keyword>mitochondrial membrane potential</keyword>
  <keyword>apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

